New ALS drug under watch: safety study launches in china
NCT ID NCT07223723
Summary
This study monitors the long-term safety of tofersen (Qalsody®) in Chinese adults with a specific genetic form of ALS. Researchers will track side effects and how the drug moves through the body in 12 participants over one year. The drug is already approved in China, so this study focuses on real-world safety after approval.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100083, China
Conditions
Explore the condition pages connected to this study.